NCT06453265 - A Study to Assess the Abuse Potential of Intranasal Cebranopadol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2024

Primary Completion Date

November 6, 2024

Study Completion Date

November 6, 2024

Conditions

Abuse, Drug

Interventions

DRUG

Cebranopadol- 600 ug

"Dose ascending cohorts~\- Cebranopadol 600 ug single dose"

DRUG

Cebranopadol- 800ug

"Dose ascending cohorts~\- Cebraopadol 800 ug single dose"

DRUG

Cebranopadol- 1000ug

"Dose ascending cohorts~\- Cebranopadol 1000 ug single dose"

DRUG

Treatment A:

Cebranopadol, dose determined in Part A

DRUG

Treatment B

Oxycodone HCl IR 40 mg

DRUG

Treatment C

Placebo

DRUG

Qualification

Oxycodone 40mg

DRUG

Qualification

Matching Placebo

Trial Locations (1)

Ohio Clinical Trials, Inc., Columbus

All Listed Sponsors

lead

Tris Pharma, Inc.

INDUSTRY